FAXAge: Randomized trial protocol testing fasting and exercise to slow human aging

Key idea

FAXAge is a randomized, controlled clinical trial protocol on medRxiv that plans to test whether fasting and exercise can slow biological aging. As a protocol, it sets out hypotheses, methods, and analyses but provides no results. Pre-specifying the plan reduces bias and clarifies how success will be judged.

Important: the public materials we reviewed do not include sample size, intervention schedules, duration, or specific outcomes.

This article is informational and not medical advice.

Why this matters

Fasting and exercise are often promoted for longevity. Without rigorous trials, it is easy to mistake correlation for causation or to overread short-term biomarker shifts. Publishing the plan up front curbs selective reporting and makes the criteria for success explicit.

What the protocol says

FAXAge is designed as a randomized controlled trial that will evaluate fasting-based and exercise interventions against appropriate controls. A protocol typically defines who can enroll, what will be measured and when, how adherence and safety are tracked, and which statistical models are used.

From the public summary, key specifics remain unknown: sample size, follow-up length, fasting format (for example, time-restricted eating or intermittent fasting), exercise modality (aerobic, resistance, or interval), and the primary and secondary endpoints. That limits what we can infer today: there is a plan, but no evidence of efficacy yet.

How “slowing aging” might be measured

Because aging unfolds over decades, trials often use surrogate endpoints—biological measurements that stand in for long-term health outcomes. Common candidates include:

• Biological age estimates from epigenetic, proteomic, or clinical composite indices
• Functional performance tests (for example, cardiorespiratory fitness, grip strength, gait speed)
• Metabolic and inflammatory markers

Regardless of the choices, good measurement practices matter:

• Test–retest reliability: results should be similar when nothing has changed biologically
• Within-person variability: day-to-day swings should not overwhelm any intervention effect
• Batch effects: differences between lab runs or reagent lots should be controlled and adjusted

Why a preprint protocol helps

Posting the protocol on medRxiv invites feedback and supports reproducibility. It is especially useful in aging science, where hype risk is high. Preprints are not peer reviewed, and protocols can evolve as trials launch, so treat them as commitments to a design—not as evidence that the design will work or that the hypotheses are true.

What this means in real life—for now

Even if the eventual RCT is positive, practical questions would remain: Which fasting schedules are tolerable long term? Which exercise modalities and doses deliver benefit with acceptable risk? How durable are biomarker changes, and do they lead to fewer diseases over time?

Individual responses vary. Caloric restriction and high-intensity exercise can be inappropriate or risky for some people, depending on health status, medications, life stage, and personal capacity.

• “Fasting” spans time-restricted eating and intermittent fasting, which can differ in effects on appetite, sleep, glucose, lipids, and hormones.
• “Exercise” includes aerobic, resistance, and interval training; dose (frequency, intensity, and total volume) strongly influences outcomes.

Without FAXAge results, there is no basis to change behavior on the strength of this protocol alone. Discuss significant diet or training changes with a clinician, especially if you have chronic conditions, take medications, are pregnant, or have a history of disordered eating.

Evidence quality at this stage

• Study type: randomized controlled trial protocol (no outcomes yet), posted as a preprint on medRxiv
• Evidence strength: planning stage; no efficacy inferences warranted
• Hype risk: moderate—public interest is high, but protocols are not results

Limitations and open questions

• Missing specifics in the public summary: unknown sample size, duration, endpoints, assays, and statistical plans
• Field-wide uncertainties: how different biological age measures align with each other and with hard clinical outcomes at the individual level
• Adherence: real-world adherence to fasting and training can be lower than in manuals; adherence strongly affects effect size
• Generalizability: results from one cohort may not apply to other ages, ancestries, or fitness levels

Practical takeaways

• Protocols are roadmaps, not proof; they reduce bias and clarify intent but do not establish benefit
• Measuring aging well requires reliable assays, attention to within-person variability, and control of batch effects
• Fasting and exercise are promising yet heterogeneous; safety and effectiveness depend on context, dose, and individual factors
• Wait for FAXAge outcomes and independent replications before drawing strong conclusions
• Discuss major diet or training changes with a healthcare professional

Sources

• Original publication: https://www.medrxiv.org/content/10.64898/2026.02.28.26347327v1.full-text
• DOI / PubMed: 10.64898/2026.02.28.26347327